Patrick A. Zweidler-Mckay

Pediatrics
1515 Holcombe Blvd Unit 37
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications

NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer.

NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer.

Journal: JCI insight
Published: November 20, 2025

Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).

Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632).

Journal: Leukemia
Published: December 12, 2024

The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia.

The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia.

Journal: HemaSphere
Published: October 02, 2024

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.

Journal: JCI insight
Published: February 08, 2024

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Journal: The Lancet. Oncology
Published: October 06, 2023

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.

Journal: Blood
Published: September 14, 2023

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.

Journal: Leukemia
Published: September 05, 2023

Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.

Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.

Journal: Leukemia
Published: May 08, 2023

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.

Journal: Blood
Published: April 07, 2023

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.

Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932.

Journal: Leukemia
Published: January 06, 2023

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report.

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report.

Journal: Blood
Published: October 12, 2022

Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.

Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.

Journal: The Lancet. Haematology
Published: June 17, 2022
Showing 1-12 of 65

Last Updated: 09/26/2026